Good day, and welcome to the Cardinal Health, Inc. Second Quarter Fiscal Year 2018 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Lisa Capodici. Please go ahead.

Thank you, Nicole. Good morning, and welcome to Cardinal Health's second quarter fiscal 2018 earnings call. I am joined today by our CEO, Mike Kaufmann; and Chief Financial Officer, Jorge Gomez. During the call, we will be making forward-looking statements. The matters addressed in these statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Please refer to our SEC filings and the forward-looking statement slide at the beginning of our presentation for a description of risks and uncertainties. Today's press release and presentation are posted on the IR section of our website at ir.cardinalhealth.com. During the discussion today, we will reference non-GAAP financial measures. Information about these measures and reconciliations to GAAP are included at the end of the slide presentation and press release. During the Q&A portion of today's call, please limit your questions to one with one follow-up, so that we may give everyone in the queue chance to ask a question. As always, the IR team will be available after this call, so feel free to reach out to us with any additional question. Now, I'd like to turn the call over to our CEO, Mike Kaufmann.

Thank you, Lisa, and good morning, everyone. We appreciate you joining us today as we report on Cardinal Health's performance for the second quarter. I'll begin with an overview of the results and then touch on our outlook for the balance of the year. Then, Jorge will provide further details in his remarks. Having worked with Jorge for many years, I couldn't be happier to have him as my partner and our CFO. Before we turn to the quarter, though, I'd like to take a moment to thank George Barrett. As you know, I took on the CEO role on January 1. We have had an incredibly smooth transition, and we look forward to George's continued guidance and contributions as Executive Chairman. Also, I am excited that Jon Giacomin has assumed leadership of our Medical segment, and we're thrilled to have him in his new role. Jon is a veteran of Cardinal Health with a proven track record as an operator. His knowledge of our customers, enterprise strategy and focus on execution will be invaluable in his new capacity. I'd also like to thank Don Casey for his contributions to Cardinal Health and we all wish him well in his new endeavor. Let's now turn to the quarter. Overall, we are very pleased with the results. Performance across the vast majority of the business was at or above plan, and this translated into the numbers, with 6% revenue growth and non-GAAP earnings per share, excluding the benefit of tax reform, of $1.31, ahead of our expectations. Among the highlights this quarter was the Pharmaceutical segment performance, where results were better than expected. And in the Medical segment, the Patient Recovery, at-Home, and naviHealth businesses all performed well. On the flip side, we have some work to do in a couple…

Thanks, Mike. I'm delighted to begin this role and to join my first earnings call as CFO. Now, before I share about our performance, I'd like to give just a few thoughts. As I enter my second month in this role, I could not be more excited about the opportunities ahead of us. I look forward to partnering with Mike, our leadership team, our Board and our investors to drive sustainable growth for Cardinal Health. Now, let me review in detail our strong financial performance in the second quarter of fiscal 2018. The financial results that I provide this morning will be on a non-GAAP basis, unless I specifically call them out as GAAP. Slide 7 of the presentation includes our GAAP to non-GAAP adjustments for the second quarter. As Mike said before, we are pleased with the second quarter results. Based on the performance year-to-date, we feel confident about Cardinal's outlook for the year. Starting with EPS, diluted EPS for Q2 was $1.51, a 13% increase versus the prior year. This includes a reduction of the federal tax rate, resulting from the recent U.S. tax reform. I will discuss this in detail in a few moments. Revenue increased 6% versus last year, totaling $35.2 billion. Total company gross margin dollars were up 16% to $1.9 billion versus the same quarter in the prior year. Consolidated SG&A increased 24% versus last year in line with our expectations. This increase was driven primarily by our recent acquisitions, most notably the Patient Recovery business. Consolidated operating earnings were $730 million, which represent 4% growth versus the prior year. Moving below the operating line, net interest and other expense was about $81 million in the quarter. The increase versus the prior year was driven by the interest on the debt issued to finance…

Thank you. We'll be taking our first question from Eric Percher from Nephron Research.

Hi. Good morning. This is actually Clayton Meyers on for Eric Percher. It's just – a good quarter on the Pharmaceutical segment. I just wanted – a few questions on that business. Particularly, it sounds to be (26:51) if I'm reading correctly that you performed better than expected on the buy-side via Red Oak. And then particularly I'm just wondering as you think about the generic market, if there is a difference in pricing between different generic categories, most notably, in oral solids and injectables, and maybe that's what we're seeing some noise from the manufacturers over the last couple of months. Thanks.

Clayton, thanks a lot for the questions. Yeah. You're right, I think we had a very good quarter in the Pharmaceutical segment, it absolutely exceeded our expectations. And as we mentioned, a lot of it had to do with Red Oak in its performance on the cost side. As I mentioned, the generic deflation is trending basically about where we expected it to be. As far as your question on solid orals and injectables, yes, the majority of our generics that we sell and when we talk about our higher margin source program are our solid orals. Most of the injectable generics that we sell are through the GPO non-source programs, which are a lower-margin business for us. So that could be a little bit difference of why you might hear some different messages from pharma manufacturers. But we feel very good about where the Pharma segment is, particularly as I mentioned, Pharma distribution, but also Specialty and Nuclear continued to perform well for us.

Great. Thanks. It's very helpful.

Great. Thanks, Clayton. Next question.

The next question comes from Ross Muken with Evercore.

Good morning, guys. So I'm just trying to dig in a bit on the Medical side to just sort of understand some of the underlying. The color was helpful. But we've got a euro that's better that should help a number of the businesses and it looked like the inventory step-up was probably a little bit less then what you originally guided, and so those should've been I think a bit of a net benefit. And so as we're thinking about the headwind, Cordis, you called out but there, you've got a product launch and it seems like that's a pretty good product launch, and that's helpful. So where really is the magnitude of the delta I guess in the traditional business coming from? I'm just trying to tease out some of the parts.

Yeah. Thanks, Ross, for the question. A couple different pieces. The first thing I want to really emphasize, and then I'll let Jorge go through some of the details of the moving part, is the overall Medical segment is doing very well that when you take apart the business and take a look at how our post-acute businesses are doing, the at-Home and the naviHealth businesses, our services businesses, our product lines, they all are doing really well. So we feel good overall about the segment, but I'll have Jorge talk a little bit about the challenges and see if we can give you maybe just a little bit more color.

Yeah, Ross. As we said before, in addition to Cordis, exam gloves is a headwind for us right now. It's been for a quarter or so now and the challenges will continue for a little while. One thing for you to remember also with respect to the core business is that the loss of VA that we had last year, we are still dealing with that headwind. Beyond that, as Mike said, the other businesses, and I indicated that on my prepared remarks, are doing really well. Your comment about FX, FX is not a headwind for us right now. As you said, it's probably a little bit of a net benefit. But remember that we have long exposures from a sales perspective but we also buy a lot of products and materials in foreign currency and so that offsets some of the benefit from FX.

That's helpful. And maybe just a quick clarification on the tax rate. So in the deck, the ETR, you kind of quoted as 29% to 31%, and then in the press release we had 28%. I'm just trying to understand the difference between the delineation of those two definitions and then really understand kind of what the trajectory is into 2019 because I recall at JP, you talked about a number more in the mid-20s.

That's a good question. The 28% that is the federal corporate tax rate. So that's a clean rate. The 29% to 30% is the effective tax rate, which includes not only the federal corporate tax rate but also all our taxes like state tax and things like that. So there is a little bit more to it on the effective tax rate. So that's the difference between those two. With respect to the second question about 2019, and I indicated that on my prepared remarks as well, we are experiencing a step-down this year is blended given the difference between the first half and the second half of the year, but we also expect a further step-down in 2019 as we experience the whole benefit for the full year of the 21% tax rate. Remember, there is also some provisions that kick in in 2019 that will offset some of the further step-down in 2019. But net-net, you should expect to see our ETR in 2019 to be lower than in 2018.

Thanks, Ross.

We'll take our next question from George Hill with RBC Capital Markets.

Hi. It's Stephen Hagan on for George. So just kind of a housekeeping item on the inventory step-up costs, with the lower impact this quarter, what's the expectation now for the full-year impact?

So Stephen, this quarter, in Q2, was the last time that we had the step-up expense. So going forward, we won't have that effect anymore.

Okay. And then on the Pharma segment, what kind of drove the strength this quarter? Was there any pull-forward of future benefit, or was it really also the Specialty and the other things you pointed out?

It was really just better-than-expected results on our generic programs in Pharmaceutical Distribution and then strength in both our Specialty businesses and our Nuclear businesses.

And our next question comes from Lisa Gill with JPMorgan.

Thanks and good morning. It's Mike Minchak in for Lisa. I guess first question, in the past, you had talked about $0.16 of investments related to customer initiatives and spending related to opioids. Just wondering if you had any update in terms of that commentary and sort of how much of that ramped in the second quarter and what's the expectation for the full year?

Yes. Sure. So a couple of pieces. As it relates to the opioids, we started to see some spending in Q2, but it was actually very minor. We took a little bit longer to get that ramped than we expected. We still expect to spend the full amount that we said we would. So you saw a little bit of a timing benefit in Q2 on not spending it, then you'll see more of a catch-up full spend in Q3 and Q4. And we actually are starting to see that spend already in January and February. So we feel good now that we're on track to see the spending go the way we expected it to now for the rest of the year. As far as the customer investments, I still feel like, as you can imagine, we did – they're still included in our outlook for the second half of the year. So we still are having ongoing conversations with the customers. And as I've mentioned before, I reiterate these are existing customers and these are some strategic initiatives that we're working through with them. And while I was hoping that we might have those finalized by now, I would still – I still feel like we will sometime this quarter.

Great. And then as a follow-up, can you talk about utilization and volume trends in the Medical segment across both the acute ambulatory and home segments and sort of how we should think about the strong flu season is impacting the results and expectations for the year in both the Pharma and Medical segments?

Yeah. With respect to utilization, that is always a difficult, I guess, metric to track and because it depends on manufacturers. And so for us, the way we think about it is we look at our customer base and how they are doing. And what I can tell you is that our businesses are performing well in terms of sales. The majority of our customers are growing and as you see more consolidation in the medical space, there will always be some winners and some losers. And so utilization for us is a function of that. We see a good growth in our key accounts in the Medical front and that's reflected on our revenue growth performance so far. With respect to the flu season, in December, we saw some activity, and we believe in January, it's picking up a little bit. From a financial standpoint for us, in Q2, flu was not really a driver but we know that over the last few weeks, it's picking up.

And our next question comes from Ricky Goldwasser with Morgan Stanley. Liza C. Garcia - Morgan Stanley & Co. LLC: Hi, guys. This is Liza on actually for Ricky. Just clarification on the tax rate for this quarter. Can you maybe dive into – is this a lower federal tax rate assumed for the December quarter in the $0.20 and also why the $0.20 is outsized relative to the expectations for the next two quarters?

Yeah. That's a good question. The way it works is the ETR is a projection for the full year. So the projected ETR is in the 21% to 31% range. So if you pick the midpoint, the first half of the year is adjusted in a way that it's kind of a catch-up entry so that the average for all of the quarters' results in a 30% rate. The first quarter rate was kind of a typical rate of 36%. And so the entry in Q2 needs to average the two quarters such that the average for the entire year is a 30% range that we're talking about. So it's a mathematical adjustment to average the rate for the entire year. Liza C. Garcia - Morgan Stanley & Co. LLC: Okay. Thank you. I guess I know you've touched on kind of a lower tax rate going into fiscal 2019, but I guess how should we think about that relative to the 5.60% (38:09) that's been called out?

Yeah. Remember the 5.60% (38:13) was an early outlook that we gave a while back and we have a lot of moving parts that we're going to be taking a look at. We still feel it's early to really talk about FY 2019. Clearly, tax rate will be one of the movers that we'll take a look at as we put together our guidance for next year. We're going to continue to take a look at our Patient Recovery business and how it's doing. So far, it's tracking as we expected it to be, but it's only been a few months, so we're going to want to get a little bit more time under our belt there. Obviously, the continued impact of the exam gloves, how Cordis is going to ramp up for us next year. And then, we'll take a look at generic programs and the net impact of customer wins and losses. Those are some of the things that we want to still play out for a few more months and another quarter or two. And then as we have in the past, in August, we'll come out with our guidance for 2019. Next question.

Our next question comes from David Larsen with Leerink.

Hi. Can you talk a bit about margin expectations for the Medical division? I know that we had talked about with, I think, 5.75% margin long-term at one point. Any thoughts on that? Thanks.

Yeah. Thanks, Dave. Yeah. If you look at the margin rate for this quarter, which was about 5.4%, that rate includes actually the inventory step-up expense related to Patient Recovery. So if you adjust for that expense, that is not going to happen on the second half of the year. We are very close to the 6% margin rate expectation that we have for the second half of this year. So we feel good about being on a path to get into those margin rates for Medical that we discussed before.

Okay. That's great. And then just any thoughts on commentary from Washington around drug pricing reform, any thoughts on what the administration might do or not and how that could impact the business? Thanks.

Yeah, and thanks a lot for the question, Dave. And just a couple of things about that. When I think about price reform and its impact on us, I'd kind of break it down into generics and branded drugs. And from a generic perspective, I think we can all agree that it tends to be the vast majority of those items are deflating and that they're roughly 90% of prescriptions in the U.S. are generics. And so from a cost effectiveness for the entire healthcare system, generics continue to be very, very cost effective for the system. So it's hard for me to imagine something in the area of generics that would be materially in the terms of the drug pricing area based on just the overall economics and the trends we're seeing in generics. As far as it goes to the branded side, as we've seen both in our guidance and others is that we're now only expecting to see somewhere in the neighborhood of 7% to 8% inflation from branded drugs. So the branded manufacturers themselves have cut back significantly on the amount of inflation or price increases that they've had. We continue to see that. And then as you're translating that into how it impacts us, as we mentioned in the past, we expect to be, and from everything we're seeing right now will be more than 90% of our branded margins are going to be non-contingent to inflation. So if you put that around, less than 10% of our branded margins are contingent to inflation, which again is down to 7% to 8%. So for us, as Cardinal, I think that this is an area that we feel good that we ought to be able to manage through very effectively however it goes in Washington.

And our next question comes from Charles Rhyee with Cowen. Charles Rhyee - Cowen & Co. LLC: Yes. Thanks for taking the questions. A lot have been asked but just maybe going back to, on Red Oak. Can you talk about sort of longer-term, when you think about the contribution here, obviously, we're talking about sort of a lower contribution year over year expected this year versus last. But as you kind of look at over the next couple of years, we do have some more launches coming. Can you think about – can you give us a sense on how maybe as we think about 2019, how that contribution could vary as we go forward? Thanks.

Yeah. We're continuing to feel really good about Red Oak. It's not just about the fact that our scale and our ability to source, but that team is just – first of all, it's a great group of folks. They're very strategic. They're constantly thinking about new ways to approach and work with our manufacturing partners, thinking about the pipeline of launches. So I feel really confident in their ability to continue to give us year-over-year benefit. As I said, it might be a little bit less going forward year over year as we continue to work through the items. But anytime we see launches and stuff, I fully expect that Red Oak will put us in the best position possible to compete in the marketplace and have the best cost position. So continue to feel really good about all the work that they're doing and the benefits that will continue to drive going forward. Charles Rhyee - Cowen & Co. LLC: Is it fair then as when we just look at the calendar of launches, is that a good proxy then just to think about sort of the incremental change in benefit from Red Oak? Or do you think we should think about Red Oak continuing to perform maybe better than what the market would look like?

Yeah. It's a great question. There is so many things that go into it. So clearly, the launches are an important piece of it, but each launch is so different. Depending on whether it's a 2-player or a 5-player, whatever number market, the type of drug, how hard it is to make, the timing of the various launches, when other players come out on current drugs that might be 2 or 3-player markets, they get continued competition. So it's hard to really pick any one item and predict it. And so as we get closer to giving 2019 guidance, we'll give you some more color around the benefits that we expect from Red Oak. But whatever the environment is, I expect that we'll be in the best position to compete with just the team we have there. Next question.

We will move on to Robert Jones from Goldman Sachs. Robert Patrick Jones - Goldman Sachs & Co. LLC: Great. Thanks for the questions. Yeah, so just I know you've kind of answered this a couple of different ways. I just wanted to go back to make sure I understood the back half of the year. Big beat in the quarter even if I adjust out the benefit for tax from both the quarter and the guidance, and yet it looks like you're really not raising the back half at all. So I guess the question really is, are you anticipating some areas getting worse? Is there something you have visibility into the back half? I know you mentioned China but that's not all that significant in the grand scheme of what you did in the quarter and then you're not really raising the guidance outside of tax?

Thanks. I appreciate the question. So let me just give you a few thoughts on that. First, for me right now it just feels a little bit early to be raising guidance. I mentioned there are some small timing type of things that we'll be absorbing like the opioids that I mentioned that had less spend in Q2 and we'll have some more spend in Q3. As Jorge mentioned, we expected Cordis profits to ramp up in our original projections, and those are ramping up as quite as well as we would have liked them to. And then also the exam gloves has been somewhat of a challenge and we're still working through our various solutions there. And then as you just mentioned, we have the $0.05 from China. So you have all those, and then as a positive, as we've said, we feel really good about where the Pharma segment's at and that we do continue to expect it to be better than expected. But at this time, when we take all those puts and takes and put them together, we just feel the right thing to do is just to at this point in time maintain our guidance adjusted for the impact of tax reform. Robert Patrick Jones - Goldman Sachs & Co. LLC: Okay. Got it. And I guess just one quick follow-up on Medical. And I feel like you do get this question at least the last few quarters, but your largest peer there focused on the acute space continues to struggle quite a bit. And one of the main areas they talk a lot about is a very challenging end-market, yet that doesn't seem to be the case even if we kind of parse out Medtronic and Cordis around what the message is that you're sharing on that core business. So is there anything, any light you can shed on this for us as far as market share shifts, maybe just a different type of customer mix, because it really has become quite divergent between the message from your core Medical business and your largest peer?

Yeah. Thanks for the question on that, too. I appreciate that. I don't want to comment on competitors' actual results. But I will say a few things. First of all, I think there has been some supply disruptions in the market for sure. But those items for us, from a profitability standpoint, have not been that significant of a driver in our Q2. And while we still see that there'll probably be some supply disruptions in three and four, we also don't expect that to be much of a negative driver for going forward for us. Now, we truly understand how difficult this is on our end-customers, and we know that it is making their lives tough and we are working incredibly hard every day to get after supply and make sure that we are on top of those things. But as far as the profit driver, it's not big. I think the big difference for us is that we made a decision years ago that we were going to change our value proposition. And that while distribution would always be part of our core and something important for us that we really needed to have a product strategy and that was going to differentiate us that we could take advantage of those rails going to those customers every single day and that we would be able to then drive our product mix and improve our overall profit. So I think the real difference here is our value proposition. And we've seen that play out in some of the recent wins over the last year or so. So I think it's really that is the difference in our value prop.

Our next question comes from Erin Wright with Credit Suisse. Erin Wilson Wright - Credit Suisse Securities (USA) LLC: Hi. Thanks. A quick follow-up on the customer initiatives you mentioned in the previous quarters as well as earlier on the call. I guess given we still don't have so much clarity there, would these expenses get pushed out into fiscal 2019? And can you just give us some greater color on what these initiatives entail? Thanks.

Thanks. No. We don't expect them to get pushed into 2019. The amount that we had set aside and had given some early color on, we still would expect to happen in the second half of our fiscal 2018. And as far as more color, I can continue to really only say that it is with existing customers. It's something that we're working on with them that both sides would really be important long-term valuable opportunities for us. And other than those two things, I really can't speak more about it. Erin Wilson Wright - Credit Suisse Securities (USA) LLC: Okay. Thanks. And on Medical, can you speak to some of the broader drivers across the international markets? Where did you see sort of pockets of growth on a geographic basis? And I think you briefly mentioned this but what's truly embedded in your guidance as it relates to the foreign exchange impact? Thanks.

Hi Erin, this is Jorge. I'm going to take that question. I would break down the international markets between Cordis and Patient Recovery. I think for Patient Recovery, what I would say is right now it's early to tell. We are on track with our deal model with respect to sales expectations in the international markets. With Cordis, it's a lot easier to see the performance in those markets. And I can tell you that the Cordis business is doing very well in Asia Pacific. We've seen tremendous growth in markets like China. We've seen a good turnaround of trends in other markets like Japan and we see some growth in places like Korea and Australia-New Zealand. For EMEA, we also see, in certain buckets, a fair amount of growth. The assumptions that we have with respect to FX in the forecast, we alluded to that before. FX is a little bit of a tailwind for us and that's what we have included in for the balance of the year, but it's not a significant driver.

And our next question comes from Brian Tanquilut with Jefferies.

Hey. This is Bryan Ross on for Brian Tanquilut. Just a quick one on the generic deflation front. I know you've kept the mid-single digit assumption unchanged for the fiscal year. But, I guess, are you seeing anything materially different trend-wise on the buy-side and the sell-side as we've moved into 2018? And then kind of where do you envision that's going as we get into the back half of the fiscal year in comparison to the first half? Is it still in that mid-single digit range? Or was the first half slightly more deflationary? And then are there any material contracts, or RFPs, coming up on the sell-side for 2018?

Yeah. Great. Remember, our calculation for generic deflation is a point-to-point calculation. So we basically look at the end of last year and to the end of this year, and we still expect, at that point, to see mid-single digits as our ultimate deflation number. And so we still feel good about that estimates and are trending there as far as – as we look at our continued trends. The piece, as I mentioned before, that's doing slightly better which is helping us is on the cost side. So deflation is tracking about where we expect, cost is tracking a little bit better, and that's driving some upside for us in Pharmaceutical Distribution. And as I mentioned, Specialty and Nuclear continue to perform better than we expected. As far as RFPs go, we don't actually really have any large account RFPs that we're renewing in our fiscal 2018 and those that are out there that are large, actually don't renew until the end of our fiscal 2019.

Got it. Thank you.

Our next question comes from Eric Coldwell with Baird. Eric W. Coldwell - Robert W. Baird & Co., Inc.: Hey, guys. I tried to back out when all of my topics were covered. So thanks very much. I'm good here.

All right. Thanks, Eric.

And we have time for one final question with John Kreger with William Blair. Courtney Owens - William Blair & Co. LLC: Hi. This is Courtney Owens on for John Kreger. Just a quick question. So can you provide us with just a little bit of an update on naviHealth? I heard you guys say that it performed pretty well during the quarter, but just would like an update kind of on what your expectations for that portion of the business going forward, and kind of what's been like the recent client uptake on that service. Thanks.

Yeah. Thanks for the question. The business – we really are excited about the business itself. It's got a really good team. I think they're on trend. We're continuing to see both providers and payers looking for help in the post-acute space and we think we have a unique model that combines both software and analytics with clinicians to be able to really provide a top-notch service to those customers. So we continue to feel good about that business. We're making continued investments in that business, because we do see it as a business that we see growing going forward. But other than that I just, again, feel really good about it and feel good about the team. Courtney Owens - William Blair & Co. LLC: Awesome. Thank you.

Thank you.

Operator, I think that was the last call?

Yes, it was. I'd like to turn the conference back over to Mike Kaufmann for any closing remarks.

Well, again, I want to thank all of you for joining us today. I know you are having a busy day. We really appreciate the questions and we look forward to talking again soon. Have a good morning.

Thank you.

And once again, ladies and gentlemen, that does conclude today's conference. We appreciate your participation today.